Physician profile
Daryl P Banta
NPI 1932299450
$5,846.57
in general payments reported to CMS, 2019-2025
38 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,712 · 2020: $693 · 2021: $655 · 2022: $505 · 2023: $288 · 2024: $643 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,596.52 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $782.29 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Advanced Respiratory, INC | $344.47 | 2019 | |
| Mylan Specialty L.P. | $282.02 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $279.12 | 2019-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $271.87 | 2019-2024 | Airsupra |
| Inari Medical, INC. | $270.17 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Philips North America LLC | $246.61 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $154.22 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $140.02 | 2024 | Acthar |
| Merck Sharp & Dohme LLC | $136.58 | 2019-2020 | |
| Insmed, INC. | $125.63 | 2019-2025 | Brinsupri, Arikayce |
| Sunovion Pharmaceuticals INC. | $119.15 | 2019 | |
| Edwards Lifesciences Corporation | $116.58 | 2019 | |
| Grifols USA, LLC | $116.35 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $101.33 | 2019-2020 | |
| Shionogi INC | $86.58 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $80.97 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $73.15 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $61.39 | 2021 | |
| Pulmonx Corporation | $43.58 | 2025 | Zephyr Delivery Catheter, Chartis Catheter, Zephyr Endobronchial Valve |
| Viatris Specialty LLC | $36.07 | 2025 | Yupelri |
| Covidien LP | $35.97 | 2019 | |
| Circassia INC. | $35.71 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $32.91 | 2019 | |
| Portola Pharmaceuticals, LLC | $32.10 | 2019 | |
| Allergan, INC. | $32.02 | 2019 | |
| Verona Pharma, INC. | $28.30 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $25.59 | 2024 | Tyvaso |
| Genzyme Corporation | $22.83 | 2019 | |
| Paratek Pharmaceuticals, INC. | $21.18 | 2020 | |
| Melinta Therapeutics, LLC | $20.96 | 2019 | |
| Optinose US, INC. | $20.00 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $19.80 | 2021 | |
| Pfizer INC. | $16.91 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.69 | 2019 | |
| Electromed, INC. | $12.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryl Banta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.